Gilead Sciences announces approval of Remdesivir in India for patients with severe Covid-19
Gilead Sciences announces approval of Remdesivir in India for patients with severe Covid-19
Indian Express
0 shares
1 views
You might like
Related news coverage
Gilead prices remdesivir, the only drug greenlighted to treat Covid
bizjournals
Remdesivir — the only drug authorized by federal regulators to treat Covid-19 patients during the pandemic — will cost $2,340..
-
Gilead slaps multi-thousand-dollar price tag on coronavirus treatment remdesivir
Proactive Investors
-
Coronavirus: China approves vaccine for military use, global deaths reach 500,000, US health secretary warns on infection surge...
Proactive Investors
-
Coronavirus outbreak: Mumbai, parts of Maharashtra to get COVID-19 drug soon
Mid-Day
-
Gilead to start trial of inhaled version of Covid-fighting remdesivir
bizjournals
Advertisement
More coverage
Gilead to start testing inhaled version of experimental coronavirus drug remdesivir, CEO says
FOXNews.com
Remdesivir, which recently received emergency use approval to treat patients with COVID-19, will be tested in an inhaled version,..
-
Coronavirus: What’s happening in the labs of pharma companies worldwide
Proactive Investors
-
Gilead to enroll pediatric patients for late-stage remdesivir study
Reuters India
-
Humanigen says lenzilumab drug delivers better recovery time for coronavirus-associated pneumonia in cross-trial analysis
Proactive Investors
-
Singapore approves Gilead's remdesivir for COVID-19 treatment
Reuters India